UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): January 19, 2010
ENOX BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
Nevada 000-53486 26-0477124
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
303-1687 Broadway W, Vancouver, BC V6J 1X2 Canada
(Address of principal executive offices)
Registrant's telephone number, including area code: (604) 637-9744
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
SECTION 4 - MATTERS RELATED TO ACCOUNTANTS AND FINANCIAL STATEMENTS
ITEM 4.01 CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT
(a) On January 19, 2010, we dismissed the firm of Seale and Beers, CPAs (Seale
and Beers") as our independent certifying accountants pursuant to the unanimous
consent of our Board of Directors. We initially retained Seale and Beers on
August 3, 2009, None of the reports of Seale and Beers, CPAs with respect to the
quarterly period ended September 30, 2009, the only period for which Seale and
Beers, CPAs provided such a report, contained an adverse opinion or disclaimer
of opinion, or was qualified or modified as to uncertainty, audit scope or
accounting principles.
During the interim period for which the Registrant engaged, there were no
disagreements with Seale and Beers, CPAs, whether or not resolved, on any matter
of accounting principles or practices, financial statement disclosure, or
auditing scope or procedure, which, if not resolved to Seale and Beers, CPAs
satisfaction, would have caused it to make reference to the subject matter of
the disagreement in connection with its report on the Registrant's financial
statements.
We have provided Seale and Beers with a copy of the foregoing disclosure, and
have requested that it furnish us with a letter addressed to the Securities and
Exchange Commission stating whether or not it agrees with such disclosure. We
are including as an Exhibit to this Form 8-K, a copy of the letter from Seale
and Beers as required by Item 304(a)(3) of Regulation S-K.
(b) On January 14, 2010, we engaged Berman & Company, P.A., as our new
independent certifying accountants. During the two most recent fiscal years and
the interim periods preceding the engagement, we have not consulted Berman &
Company, P.A. regarding any of the matters set forth in Item 304(a)(1)(v)of
Regulation S-K..
SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
Exhibit No. Description
----------- -----------
16.1 Letter from Seale and Beer, CPAs regarding its concurrence
or disagreement with the statements made by Enox Biopharma,
Inc. in this current report Form 8-K.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ENOX BIOPHARMA, INC.
Date: January 19, 2010 By /s/ Itamar David
------------------------------------
Itamar David
Chief Financial Officer
3